TTNP
Income statement / Annual
Last year (2024), Titan Pharmaceuticals, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Titan Pharmaceuticals, Inc.'s net income was -$4.71 M.
See Titan Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$184,000.00 |
$60,000.00 |
$1.53 M |
$4.84 M |
$3.61 M |
$5.91 M |
$215,000.00 |
$15.07 M |
$1.67 M |
| Cost of Revenue |
$0.00
|
$112,000.00
|
$196,000.00
|
$199,000.00
|
$472,000.00
|
$1.29 M
|
$538,000.00
|
$9.65 M
|
$6.13 M
|
$4.68 M
|
| Gross Profit |
$0.00
|
$72,000.00
|
-$136,000.00
|
$1.33 M
|
$4.37 M
|
$2.32 M
|
$5.37 M
|
-$9.43 M
|
$8.94 M
|
-$3.00 M
|
| Gross Profit Ratio |
0
|
0.39
|
-2.27
|
0.87
|
0.9
|
0.64
|
0.91
|
-43.87
|
0.59
|
-1.8
|
| Research and Development Expenses |
$0.00
|
$1.91 M
|
$4.76 M
|
$5.69 M
|
$5.92 M
|
$7.24 M
|
$7.48 M
|
$9.65 M
|
$6.13 M
|
$4.68 M
|
| General & Administrative Expenses |
$4.56 M
|
$5.55 M
|
$6.03 M
|
$4.99 M
|
$5.80 M
|
$5.40 M
|
$0.00
|
$5.07 M
|
$4.60 M
|
$3.76 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.56 M
|
$5.55 M
|
$6.03 M
|
$4.99 M
|
$5.80 M
|
$11.93 M
|
$6.87 M
|
$5.07 M
|
$4.60 M
|
$3.76 M
|
| Other Expenses |
$0.00
|
-$183,000.00
|
-$497,000.00
|
-$84,000.00
|
$1.72 M
|
$17,000.00
|
-$6,000.00
|
-$55,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.56 M
|
$7.28 M
|
$10.30 M
|
$10.68 M
|
$11.72 M
|
$19.17 M
|
$13.64 M
|
$14.72 M
|
$10.72 M
|
$8.43 M
|
| Cost And Expenses |
$0.00
|
$7.46 M
|
$10.30 M
|
$10.88 M
|
$12.19 M
|
$20.46 M
|
$14.18 M
|
$14.72 M
|
$10.72 M
|
$8.43 M
|
| Interest Income |
$0.00
|
$5,000.00
|
$53,000.00
|
$1,000.00
|
$769,000.00
|
$967,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$1,000.00
|
$769,000.00
|
$967,000.00
|
$887,000.00
|
$369,000.00
|
$37,000.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$112,000.00
|
$196,000.00
|
$221,000.00
|
$292,000.00
|
$244,000.00
|
$380,000.00
|
$417,000.00
|
$377,000.00
|
$358,000.00
|
| EBITDA |
-$4.56 M |
-$7.17 M |
-$10.04 M |
-$9.13 M |
-$7.06 M |
-$6.28 M |
-$7.88 M |
-$14.09 M |
$4.72 M |
-$6.40 M |
| EBITDA Ratio |
0
|
-38.94
|
-167.32
|
-5.98
|
-1.46
|
-1.74
|
-1.33
|
-65.51
|
0.31
|
-3.83
|
| Operating Income Ratio |
0
|
-39.55
|
-170.58
|
-6.13
|
-1.52
|
-4.66
|
-1.4
|
-67.45
|
0.29
|
-4.04
|
| Total Other Income/Expenses Net |
-$149,000.00
|
$1.71 M
|
$29,000.00
|
$578,000.00
|
-$56,000.00
|
$386,000.00
|
-$759,000.00
|
$195,000.00
|
$792,000.00
|
-$4.52 M
|
| Income Before Tax |
-$4.71 M
|
-$5.57 M
|
-$10.21 M
|
-$8.78 M
|
-$7.41 M
|
-$16.46 M
|
-$9.02 M
|
-$14.31 M
|
$5.14 M
|
-$11.28 M
|
| Income Before Tax Ratio |
0
|
-30.27
|
-170.1
|
-5.75
|
-1.53
|
-4.56
|
-1.53
|
-66.54
|
0.34
|
-6.75
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$29,000.00
|
-$662,000.00
|
$13.32 M
|
-$369,000.00
|
-$1.65 M
|
-$250,000.00
|
-$792,000.00
|
$4.52 M
|
| Net Income |
-$4.71 M
|
-$5.57 M
|
-$10.18 M
|
-$8.11 M
|
-$20.73 M
|
-$16.09 M
|
-$9.02 M
|
-$14.31 M
|
$5.14 M
|
-$11.28 M
|
| Net Income Ratio |
0
|
-30.27
|
-169.62
|
-5.32
|
-4.28
|
-4.46
|
-1.53
|
-66.54
|
0.34
|
-6.75
|
| EPS |
-5.23 |
-7.41 |
-15.15 |
-16.68 |
-109.88 |
-12602.35 |
-47.59 |
-121.48 |
44.71 |
-101.24 |
| EPS Diluted |
-5.23 |
-7.41 |
-15.15 |
-16.68 |
-109.88 |
-12602.35 |
-47.59 |
-121.34 |
36.01 |
-101.24 |
| Weighted Average Shares Out |
$899,000.00
|
$752,000.00
|
$671,700.00
|
$486,500.00
|
$188,650.00
|
$1,276.67
|
$189,598.00
|
$117,775.00
|
$115,209.00
|
$111,404.00
|
| Weighted Average Shares Out Diluted |
$899,000.00
|
$752,000.00
|
$671,700.00
|
$486,500.00
|
$188,650.00
|
$1,276.67
|
$189,598.00
|
$117,908.00
|
$119,208.00
|
$111,404.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
